Loading…
Trinity Biotech plc is projected to decline to $0.3601 by 2027, a -7% move from its current price of $0.3868. TRIB is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $0.3651 | $0.3864 | $0.4091 | -0.09% |
| Jul 14 | $0.3562 | $0.3861 | $0.4185 | -0.18% |
| Jul 15 | $0.3495 | $0.3857 | $0.4257 | -0.27% |
| Jul 16 | $0.3439 | $0.3854 | $0.4319 | -0.36% |
| Jul 17 | $0.339 | $0.385 | $0.4373 | -0.46% |
| Jul 18 | $0.3346 | $0.3847 | $0.4423 | -0.55% |
| Jul 19 | $0.3306 | $0.3843 | $0.4468 | -0.64% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.3306 | $0.3843 | $0.4468 | -0.64% |
| Week 2 | $0.3086 | $0.3819 | $0.4725 | -1.27% |
| Week 3 | $0.2923 | $0.3794 | $0.4926 | -1.90% |
| Week 4 | $0.279 | $0.377 | $0.5096 | -2.53% |
| Week 5 | $0.2675 | $0.3746 | $0.5247 | -3.15% |
| Week 6 | $0.2574 | $0.3722 | $0.5383 | -3.77% |
| Week 7 | $0.2483 | $0.3699 | $0.551 | -4.38% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Trinity Biotech plc (TRIB) is a healthcare company that engages in acquiring, developing, manufacturing, and marketing medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market across the Americas, Asia, Africa, and Europe. Its portfolio includes diagnostic tests and instrumentation that detect infectious diseases; sexually transmitted diseases such as syphilis and herpes; SARS-CoV-2; and a range of other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in diabetes monitoring and risk identification. It also provides laboratory-testing services for autoimmune disorders and partners with independent distributors and strategic partners to reach public health authorities and clinical laboratories.
Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland, with a collaboration agreement with a bioinformatics company to analyze clinical trial data for EpiCapture, a molecular diagnostics venture.
The company operates within the Healthcare sector and focuses on clinical laboratory and POC diagnostics on a global scale. With its described product lines and services, the firm targets multiple regions and a broad range of diagnostic needs in the medical field.
TRIB trades in the small-cap healthcare space with a current price of $0.406 and a market capitalization of $8.22M. It is ranked 5100 by market cap among listed assets. The price outlook derived from the provided forecast suggests a mixed near term with potential upside in the longer horizon.
For 2026 the average forecast is $0.406, moving higher in subsequent years toward longer-term bullish readings.
Notably, the forecast shows bullish sentiment in 2029, 2030, 2035, 2040, and 2050, with 2030 and 2050 presenting meaningful upside in average prices and ROI. The longer-term path indicates rising averages culminating in an average price of $1.11 by 2050 and a maximum forecast of $2.54 in that year, though the near term features several flatter years and occasional drawdowns.
Investors should be aware that these are estimates and not guarantees, and that near-term risk exists alongside longer-term upside potential across multiple milestones in the forecast.
A major floor 75.0% below — a decisive break under it would weaken the trend.
The nearest floor, 12.1% below — buyers have tended to step in here.
The nearest ceiling, 88.7% above — a clean break opens room to run.
A major ceiling 126.6% above — clearing it would confirm fresh momentum.
Key TRIB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TRIB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.396 | Sell | $0.3917 | Sell |
| MA 10 | $0.389 | Sell | $0.4051 | Sell |
| MA 20 | $0.463 | Sell | $0.4531 | Sell |
| MA 50 | $0.565 | Sell | $0.5409 | Sell |
| MA 100 | $0.6231 | Sell | $0.621 | Sell |
| MA 200 | $0.7764 | Sell | $0.7335 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 35.88 | Neutral |
| Stoch RSI (14) | 80.43 | Sell |
| CCI (20) | -45.10 | Neutral |
| Williams %R (14) | -79.17 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | 8.33 | Buy |
| Bollinger %B (20,2) | 0.35 | Neutral |
| Stochastic %K (14) | 20.83 | Neutral |
| TRIX (15) | -1.64 | Sell |
| Awesome (5,34) | -0.16 | Sell |
| Ultimate (7,14,28) | 41.17 | Neutral |
| Momentum (10) | 0.04 | Buy |
| Aroon Osc (25) | -56.00 | Sell |
| Hull MA (9) | 0.39 | Sell |
| ADX (14) | 28.27 | Sell |
| ATR (14) | 0.02 | Info |
The near-term technical picture remains bearish, with an RSI of 40 signaling subdued momentum. The price is trading below the 50-day simple moving average at $0.5846 and well below the 200-day simple moving average at $0.7924, indicating continued softness.
In the last 30 days, the price traded in a range from $0.266 to $0.6198, highlighting notable volatility. Key near-term levels include support at $0.34 and resistance at $0.73, which may come into play as price attempts to stabilize. The annualized volatility sits at 100%, underscoring the heightened fluctuations around TRIB.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.34 | $0.3868 | $0.4025 | 0% | Neutral | |
| $0.2613 | $0.3601 | $0.5367 | -7% | Neutral | |
| $0.271 | $0.3969 | $0.6303 | +3% | Neutral | |
| $0.3169 | $0.4889 | $0.815 | +26% | Bullish | |
| $0.3266 | $0.5283 | $0.9168 | +37% | Bullish | |
| $0.2568 | $0.4341 | $0.7798 | +12% | Neutral | |
| $0.2588 | $0.4564 | $0.8454 | +18% | Neutral | |
| $0.2405 | $0.4417 | $0.8409 | +14% | Neutral | |
| $0.2314 | $0.442 | $0.8629 | +14% | Neutral | |
| $0.3419 | $0.6788 | $1.36 | +75% | Bullish | |
| $0.3056 | $0.6791 | $1.49 | +76% | Bullish | |
| $0.4756 | $1.06 | $2.43 | +173% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.34 | $0.3868 | $0.4487 | +0.00% |
| August 2026 | $0.2883 | $0.3492 | $0.4405 | -9.72% |
| September 2026 | $0.2897 | $0.3559 | $0.4583 | +1.91% |
| October 2026 | $0.2691 | $0.3346 | $0.4385 | -5.96% |
| November 2026 | $0.2364 | $0.2971 | $0.395 | -11.22% |
| December 2026 | $0.2355 | $0.2988 | $0.4025 | +0.58% |
Click any year to see its month-by-month TRIB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect TRIB to range from $0.34 to $0.4025 through 2026. The $0.3868 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The TRIB price prediction for 2027 points to an average of $0.3601 (low $0.2613, high $0.5367) — a potential decline of -7% on today's $0.3868. A consolidation phase looks the most probable path here.
In 2028, TRIB is projected to trade between $0.271 and $0.6303, averaging $0.3969 — a potential gain of +3% from today's $0.3868. That is up +10% on the projected 2027 average. Price action looks broadly range-bound.
Trinity Biotech plc's 2029 outlook centres on $0.4889, within a $0.3169 to $0.815 range. That is up +23% on the projected 2028 average. That marks a +26% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, TRIB could reach as high as $0.9168, with a base case around $0.5283 and support toward $0.3266 — roughly +37% from $0.3868. Momentum favours further upside here.
Expect TRIB to range from $0.2568 to $0.7798 through 2031. The $0.4341 average target implies a +12% move from current prices. That is -18% versus the projected 2030 average. A consolidation phase looks the most probable path here.
The TRIB price prediction for 2032 points to an average of $0.4564 (low $0.2588, high $0.8454) — a potential gain of +18% on today's $0.3868. Price action looks broadly range-bound.
In 2033, TRIB is projected to trade between $0.2405 and $0.8409, averaging $0.4417 — a potential gain of +14% from today's $0.3868. That is -3% versus the projected 2032 average. A consolidation phase looks the most probable path here.
Trinity Biotech plc's 2034 outlook centres on $0.442, within a $0.2314 to $0.8629 range. That is up 0% on the projected 2033 average. That marks a +14% change versus current levels. Price action looks broadly range-bound.
By 2035, TRIB could reach as high as $1.36, with a base case around $0.6788 and support toward $0.3419 — roughly +75% from $0.3868. Buyers look set to stay in control over this stretch.
Expect TRIB to range from $0.3056 to $1.49 through 2040. The $0.6791 average target implies a +76% move from current prices. That is up 0% on the projected 2035 average. Momentum favours further upside here.
The TRIB price prediction for 2050 points to an average of $1.06 (low $0.4756, high $2.43) — a potential gain of +173% on today's $0.3868. Buyers look set to stay in control over this stretch.
Investing $1,000 in TRIB today (≈ 2,585.315408 TRIB) could be worth
$2,732.65
+$1,732.65 (+173%) by 2050 · US Dollar
Based on the average projected TRIB price of $1.06 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TRIBwould be worth at today's price.
$1,000 invested in TRIB on Jul 10, 2025 (≈ 1,282.051329 TRIB) would be worth
$495.9
-$504.1 (-50.4%) today · 0.50× · US Dollar
Based on a TRIB entry price of $0.78 vs. today's $0.3868.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.38 | $1,017.89 | +1.8% |
| 1 month ago | $0.69 | $560.58 | -43.9% |
| 3 months ago | $0.71 | $544.79 | -45.5% |
| 6 months ago | $0.71 | $544.79 | -45.5% |
| 1 year ago | $0.78 | $495.9 | -50.4% |
| All time (5.0y) ago | $11.3 | $34.23 | -96.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TRIB forecast.
Our base-case forecast reaches $0.77 around 2050.
Implied market cap at $0.77: $15.59M
The multi-year forecast paints a path of stronger gains later in the horizon. For 2029 the average price is forecast at $0.5116 with a bullish sentiment and a 26% ROI, climbing to an average of $0.5482 in 2030 with a 35% ROI. The upward trajectory continues into 2035 with an average of $0.7117 and a 75.3% ROI, and into 2040 with an average of $0.6961 and a 71.5% ROI.
By 2050, the average price is forecast at $1.11 with a 172.4% ROI, and a bullish sentiment remains. The 2040 maximum is projected at $1.53 and the 2050 maximum at $2.54, illustrating the potential upside across the longer horizon.
These figures reflect estimates of future price paths and are not guaranteed. The assessment recognizes that the asset experiences variability and that longer-term upside is accompanied by near-term risk, including a negative year in 2027 with a -7.5% ROI and a neutral sentiment. Investors should weigh these projections against their risk tolerance and market conditions.
Tap a question to reveal the answer.
In 2030 the forecast shows min $0.3387, avg $0.5482, max $0.9519 with an ROI of 35% and a BULLISH sentiment.
Near term shows mixed signals (2026 avg $0.406 with 0% ROI and 2027 avg $0.3755 with -7.5% ROI and NEUTRAL sentiment), but longer-term forecasts turn bullish with 2029 avg $0.5116 (ROI 26%), 2030 avg $0.5482 (ROI 35%), 2035 avg $0.7117 (ROI 75.3%), 2040 avg $0.6961 (ROI 71.5%), and 2050 avg $1.11 (ROI 172.4%). These are estimates, not guarantees, and should be weighed against risk tolerance.
The 2040 forecast shows a max of $1.53 and an average of $0.6961, so reaching $1 is within the forecast path, though not guaranteed.
The 2026 forecast provides an average of $0.406, a min of $0.34, and a max of $0.4285 with 0% ROI and a NEUTRAL sentiment.
Bullish years appear in 2029 (avg $0.5116, max $0.8534, ROI 26%), 2030 (avg $0.5482, max $0.9519, ROI 35%), 2035 (avg $0.7117, max $1.42, ROI 75.3%), 2040 (avg $0.6961, max $1.53, ROI 71.5%), and 2050 (avg $1.11, max $2.54, ROI 172.4%).
Trinity Biotech plc Community Discussion
0Share your Trinity Biotech plc price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.